New Delhi: Novo Nordisk A / S is considering improving sales guidelines for obesity drugs after a strong introduction to new drugs called Wegovy, Chief Executive Officer (CEO) Lars Fruggenard Jorgensen said in an interview.
“It is fair to say that the prospect here is better than we guide,” Jorgenson said.
“Clinical profiles are better than we expect, market acceptance is very strong, and we also see that even in the market without wegovy that the obesity market was also established.” Novo previously said it was aimed at more than double the sale of obesity in 2025, to around $ 1.8 billion.
The company has not yet decided a certain new guide and is waiting to see more data about Wegovy’s performance and to supply drugs to stabilize, Jorgensen said.
Wegovy, which was approved by US food and drug administration in June, helped patients lose around 15% of their average weight.
In about five weeks, the company saw many recipes for Wegovy when Saxenda had been produced in several years, Jorgensen said.
“The number of initial scripts significantly exceeded our expectations, and then we experienced supply problems and we must face a more flat developments in the new script,” he said.
“We expect a more solid building, which we saw in the past, when we launched a new product.” Novo also made the Saxate weight-lowering drug, which was launched in the US in 2015 and is expected to lose patent protection in the coming years.
The room is seen as a growth road for Novo, which is known mainly as a diabetes drug maker.
Novo can increase the sales target of obesity drugs after star demand
